

Angel Lanas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/446143/publications.pdf>

Version: 2024-02-01

265
papers

17,420
citations

28736

57
h-index

17891

125
g-index

298
all docs

298
docs citations

298
times ranked

19747
citing authors

#	ARTICLE	IF	CITATIONS
1	Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opinion on Drug Safety, 2022, 21, 373-384.	1.0	36
2	Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology, 2022, 20, 2243-2257.	2.4	15
3	1,4-Dihydropyridine as a Promising Scaffold for Novel Antimicrobials Against Helicobacter pylori. Frontiers in Microbiology, 2022, 13, .	1.5	4
4	Management of Helicobacter Pylori Infection and Effectiveness Rates in Daily Clinical Practice in Spain: 2010â€“2019. Antibiotics, 2022, 11, 698.	1.5	4
5	COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. Digestive Diseases, 2021, 39, 119-139.	0.8	88
6	The burden of musculoskeletal pain and the role of topical non-steroidal anti-inflammatory drugs (NSAIDs) in its treatment. Ten underpinning statements from a global pain faculty. Current Medical Research and Opinion, 2021, 37, 287-292.	0.9	25
7	Interobserver Agreement Among Pathologists in the Differentiation of Sessile Serrated From Hyperplastic Polyps. Gastroenterology, 2021, 160, 452-454.e1.	0.6	29
8	Familial Colorectal Cancer and Genetic Susceptibility: Colorectal Risk Variants in First-Degree Relatives of Patients With Colorectal Cancer. Clinical and Translational Gastroenterology, 2021, 12, e00301.	1.3	3
9	Endoscopic diagnosis and management of nonvariceal upper gastrointestinal hemorrhage (NVUGIH): European Society of Gastrointestinal Endoscopy (ESGE) Guideline â€“ Update 2021. Endoscopy, 2021, 53, 300-332.	1.0	215
10	Proton Pump Inhibitor (PPI) co-therapy and gastrointestinal bleeding with antithrombotic drugs: a step forward but not enough. European Journal of Internal Medicine, 2021, 85, 23-24.	1.0	1
11	Su049 A SECOND FIT AFTER A FIRST WEAK POSITIVE ONE AS A USEFUL STRATEGY TO REDUCE COLONOSCOPY LOAD IN CRC SCREENING. Gastroenterology, 2021, 160, S-595.	0.6	0
12	Sa099 REBLEEDING, ISCHEMIC EVENT AND DEATH RISKS AFTER GASTROINTESTINAL BLEEDING AMONG USERS OF DUAL ANTIPLATELET THERAPY AFTER A PERCUTANEOUS CORONARY INTERVENTION.. Gastroenterology, 2021, 160, S-421.	0.6	0
13	The Addition of Other Fecal Biomarkers Does Not Improve the Diagnostic Accuracy of Immunochemical Fecal Occult Blood Test Alone in a Colorectal Cancer Screening Cohort. Frontiers in Medicine, 2021, 8, 665786.	1.2	3
14	Evidence-Based Selection on the Appropriate FIT Cut-Off Point in CRC Screening Programs in the COVID Pandemic. Frontiers in Medicine, 2021, 8, 712040.	1.2	5
15	Fighting the Antibiotic Crisis: Flavonoids as Promising Antibacterial Drugs Against Helicobacter pylori Infection. Frontiers in Cellular and Infection Microbiology, 2021, 11, 709749.	1.8	16
16	New Trends and Advances in Non-Variceal Gastrointestinal Bleedingâ€”Series II. Journal of Clinical Medicine, 2021, 10, 3045.	1.0	2
17	A Clinical Decision Web to Predict ICU Admission or Death for Patients Hospitalised with COVID-19 Using Machine Learning Algorithms. International Journal of Environmental Research and Public Health, 2021, 18, 8677.	1.2	12
18	Predictive Value of Genetic Risk Scores in the Development of Colorectal Adenomas. Digestive Diseases and Sciences, 2021, , 1.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Â«In MemoriamÂ» Ricardo SÃ¡inz Samitier. GastroenterologÃ­a Y HepatologÃ­a, 2021, 44, 537-538.	0.2	0
20	Public health impact of low-dose aspirin on colorectal cancer, cardiovascular disease and safety in the UK â€“ Results from micro-simulation model. IJC Heart and Vasculature, 2021, 36, 100851.	0.6	2
21	Platelets induce free and phospholipid-esterified 12-hydroxyeicosatetraenoic acid generation in colon cancer cells by delivering 12-lipoxygenase. Journal of Lipid Research, 2021, 62, 100109.	2.0	11
22	European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain. Antibiotics, 2021, 10, 13.	1.5	12
23	Thermal Liquid Biopsy (TLB) Focused on Benign and Premalignant Pancreatic Cyst Diagnosis. Journal of Personalized Medicine, 2021, 11, 25.	1.1	7
24	A Patient Self-Made Point-of-Care Fecal Test Improves Diagnostic Accuracy Compared with Fecal Calprotectin Alone in Inflammatory Bowel Disease Patients. Diagnostics, 2021, 11, 2323.	1.3	1
25	Aspirin and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). , 2020, , 186-191.		0
26	Variation in Colonoscopy Performance Measures According to Procedure Indication. Clinical Gastroenterology and Hepatology, 2020, 18, 1216-1223.e2.	2.4	22
27	Validation of miR-1228-3p as Housekeeping for MicroRNA Analysis in Liquid Biopsies from Colorectal Cancer Patients. Biomolecules, 2020, 10, 16.	1.8	9
28	Mo1618 THE USE OF A QUICK AND EASY FAECAL TEST AS A TOOL TO AVOID NON-PATHOLOGICAL COLONOSCOPIES AND PRIORITIZE HIGH RISK SYMPTOMATIC PATIENTS. Gastroenterology, 2020, 158, S-918.	0.6	0
29	OC.08.3 THE â€œDICAâ€-ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS: AN INTERNATIONAL STUDY. Digestive and Liver Disease, 2020, 52, S27.	0.4	0
30	Reducing the Cut-Off Value of the Fecal Immunochemical Test for Symptomatic Patients Does Not Improve Diagnostic Performance. Frontiers in Medicine, 2020, 7, 410.	1.2	9
31	Prospective, study comparing the accuracy of two different stool antigen tests (Premier Platinum) Tj ETQq1 1 0.784314 rgBT /Overlo GastroenterologÃ­a Y HepatologÃ­a, 2020, 43, 117-125.	0.2	6
32	Quantitative analysis of p16 methylation in Barrett's carcinogenesis. Annals of Diagnostic Pathology, 2020, 47, 151554.	0.6	1
33	Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H. pylori management (Hpâ€™EuReg). Helicobacter, 2020, 25, e12686.	1.6	27
34	Colonic diverticular disease. Nature Reviews Disease Primers, 2020, 6, 20.	18.1	125
35	Small Molecule Inhibitors of the Response Regulator ArsR Exhibit Bactericidal Activity against Helicobacter pylori. Microorganisms, 2020, 8, 503.	1.6	14
36	Dietary Fat Patterns and Outcomes in Acute Pancreatitis in Spain. Frontiers in Medicine, 2020, 7, 126.	1.2	4

#	ARTICLE	IF	CITATIONS
37	Effect of Proton Pump Inhibitors on Risks of Upper and Lower Gastrointestinal Bleeding among Users of Low-Dose Aspirin: A Population-Based Observational Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 928.	1.0	9
38	The combination of quantitative faecal occult blood test and faecal calprotectin is a cost-effective strategy to avoid colonoscopies in symptomatic patients without relevant pathology. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092078.	1.4	14
39	Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019: benefits and risks of antithrombotic therapy for cardiovascular disease prevention. <i>Ecancermedalscience</i> , 2020, 14, 998.	0.6	4
40	No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 1526.	1.0	4
41	Identifying potential novel drugs against <i>Helicobacter pylori</i> by targeting the essential response regulator HsrA. <i>Scientific Reports</i> , 2019, 9, 11294.	1.6	35
42	Omega-3 Polyunsaturated Fatty Acids and Their Bioactive Metabolites in Gastrointestinal Malignancies Related to Unresolved Inflammation. A Review. <i>Frontiers in Pharmacology</i> , 2019, 10, 852.	1.6	24
43	Thermal Liquid Biopsy (TLB): A Predictive Score Derived from Serum Thermograms as a Clinical Tool for Screening Lung Cancer Patients. <i>Cancers</i> , 2019, 11, 1012.	1.7	12
44	Su1267 â€œ Management of <i>Helicobacter Pylori</i> Infection At Primary Care Level. the Implementation of Specific Counselling Improves Eradication Rates. <i>Gastroenterology</i> , 2019, 156, S-524.	0.6	0
45	Tu2036 â€œ A Patient Self-Made One Step Quick Faecal Test Reduces Unnecessary Colonoscopies and Prioritizes High Risk Symptomatic Patients. <i>Gastroenterology</i> , 2019, 156, S-1176-S-1177.	0.6	0
46	Aspirin, cancer, and bleeding: an equation to solve. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 815-816.	3.7	0
47	Mo1732 â€œ Genetic Risk Score to Identify Individuals with an Increased Risk of Colorectal Adenomas. <i>Gastroenterology</i> , 2019, 156, S-825.	0.6	0
48	Risk of rebleeding, vascular events and death after gastrointestinal bleeding in anticoagulant and/or antiplatelet users. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 919-929.	1.9	29
49	Proton pump inhibitors, adverse events and increased risk of mortality. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1043-1053.	1.0	44
50	Mo1276 â€œ No Differences in Gi Bleeding Risk Between Clopidogrel-, Ticagrelor- Or Prasugrel- Based Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. <i>Gastroenterology</i> , 2019, 156, S-743.	0.6	1
51	Design, Synthesis, and Efficacy Testing of Nitroethylene- and 7-Nitrobenzoxadiazol-Based Flavodoxin Inhibitors against <i>Helicobacter pylori</i> Drug-Resistant Clinical Strains and in <i>Helicobacter pylori</i> -Infected Mice. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 6102-6115.	2.9	23
52	Mo1636 â€œ The Addition of Other Faecal Biomarkers to Immunological Faecal Occult Blood Test is Not Effective to Avoid Normal Colonoscopies in a Colorectal Cancer Screening Program. <i>Gastroenterology</i> , 2019, 156, S-811.	0.6	0
53	Fecal Hemoglobin Concentration, a Good Predictor of Risk of Advanced Colorectal Neoplasia in Symptomatic and Asymptomatic Patients. <i>Frontiers in Medicine</i> , 2019, 6, 91.	1.2	16
54	Low-dose aspirin and risk of upper/lower gastrointestinal bleeding by bleed severity: a cohort study with nested case-control analysis using primary care electronic health records from the United Kingdom. <i>Annals of Medicine</i> , 2019, 51, 182-192.	1.5	12

#	ARTICLE	IF	CITATIONS
55	Management of <i>Helicobacter pylori</i> infection at the primary care level. The implementation of specific counseling improves eradication rates. <i>Helicobacter</i> , 2019, 24, e12586.	1.6	9
56	International Consensus Guidelines for Nonvariceal Gastrointestinal Bleeding: A Step Forward. <i>Annals of Internal Medicine</i> , 2019, 171, 853.	2.0	5
57	Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00003.	1.3	53
58	Repurposing Dihydropyridines for Treatment of <i>Helicobacter pylori</i> Infection. <i>Pharmaceutics</i> , 2019, 11, 681.	2.0	16
59	Genetic susceptibility in the development of colorectal adenomas according to family history of colorectal cancer. <i>International Journal of Cancer</i> , 2019, 144, 489-502.	2.3	10
60	Incidence of Upper and Lower Gastrointestinal Bleeding in New Users of Low-Dose Aspirin. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 887-895.e6.	2.4	27
61	Short- and long-term clinical outcomes of self-expandable metal stents inserted for colorectal obstruction and efficacy of different insertion techniques. <i>Gastroenterology and Hepatology</i> , 2019, 42, 157-163.	0.2	7
62	International Consensus on Diverticulosis and Diverticular Disease. Statements from the 3rd International Symposium on Diverticular Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 57-66.	0.5	21
63	Adding genetic scores to risk models in colorectal cancer. <i>Oncotarget</i> , 2019, 10, 4803-4804.	0.8	2
64	The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 39-44.	0.5	2
65	Course of the Diverticular Disease: What is changing?. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 11-16.	0.5	1
66	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 231-241.	3.7	156
67	Transcriptional regulators: valuable targets for novel antibacterial strategies. <i>Future Medicinal Chemistry</i> , 2018, 10, 541-560.	1.1	18
68	Non-variceal upper gastrointestinal bleeding. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18020.	18.1	95
69	Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. <i>Gut</i> , 2018, 67, 1757-1768.	6.1	185
70	Identification of the tumour transition states occurring during EMT. <i>Nature</i> , 2018, 556, 463-468.	13.7	1,083
71	Mechanisms of Damage to the Gastrointestinal Tract From Nonsteroidal Anti-Inflammatory Drugs. <i>Gastroenterology</i> , 2018, 154, 500-514.	0.6	310
72	Thermal liquid biopsy for monitoring melanoma patients under surveillance during treatment: A pilot study. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 1701-1710.	1.1	19

#	ARTICLE	IF	CITATIONS
73	Preguntas y errores en el diagnóstico y manejo de la anemia en pacientes con hemorragia digestiva. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 63-76.	0.2	6
74	Importance of endoscopist quality metrics for findings at surveillance colonoscopy: The detection surveillance paradox. <i>United European Gastroenterology Journal</i> , 2018, 6, 622-629.	1.6	16
75	Differing disintegration and dissolution rates, pharmacokinetic profiles and gastrointestinal tolerability of over the counter ibuprofen formulations. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 223-233.	1.2	5
76	Open questions and misconceptions in the diagnosis and management of anemia in patients with gastrointestinal bleeding. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2018, 41, 63-76.	0.0	5
77	Detection of serrated lesions in proximal colon by simulated sigmoidoscopy vs faecal immunochemical testing in a multicentre, pragmatic, randomised controlled trial. <i>United European Gastroenterology Journal</i> , 2018, 6, 1527-1537.	1.6	7
78	Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?. <i>PLoS ONE</i> , 2018, 13, e0203957.	1.1	31
79	Low dose aspirin, <i>H. pylori</i> infection, and the risk of upper gastrointestinal bleeding. <i>Medical Journal of Australia</i> , 2018, 209, 297-298.	0.8	3
80	Evidence for <i>PTGER4</i> , <i>PSCA</i> , and <i>MBOAT7</i> as risk genes for gastric cancer on the genome and transcriptome level. <i>Cancer Medicine</i> , 2018, 7, 5057-5065.	1.3	22
81	Management of colonic diverticular disease in the third millennium: Highlights from a symposium held during the United European Gastroenterology Week 2017. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481877130.	1.4	33
82	Progress and challenges in the management of diverticular disease: which treatment?. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481878905.	1.4	27
83	Su1748 - Limited Impact of Specific Recommendations Issued for Surveillance Colonoscopies in a Colorectal Cancer Prevention Program. <i>Gastroenterology</i> , 2018, 154, S-576-S-577.	0.6	0
84	686 - Risk of Both upper and Lower Gastrointestinal Bleeding Associated with Low-Dose Acetylsalicylic Acid and Proton Pump Inhibitors Among Nearly 400,000 Individuals in Routine General Practice in the United Kingdom. <i>Gastroenterology</i> , 2018, 154, S-136-S-137.	0.6	1
85	Upper gastrointestinal bleeding in critically ill patients: proton-pump inhibitors, histamine-2 receptor antagonists or placebo? Many questions remain unanswered. <i>Current Medical Research and Opinion</i> , 2018, 34, 1881-1883.	0.9	4
86	NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1031-1043.	1.3	98
87	Su1004 - Combination of Quantitative Faecal Occult Blood Test and Fecal Calprotectin is a Cost-Effective Strategy to Avoid Non Pathological Colonoscopies in Symptomatic Patients. <i>Gastroenterology</i> , 2018, 154, S-450-S-451.	0.6	0
88	Rifaximin for the Management of Colonic Diverticular Disease: far Beyond a Simple Antibiotic. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2018, 27, 351-355.	0.5	6
89	Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehw454.	1.0	86
90	Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 52-61.	2.3	38

#	ARTICLE	IF	CITATIONS
91	Peptic ulcer disease. <i>Lancet</i> , The, 2017, 390, 613-624.	6.3	570
92	Aspirin and omeprazole for secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 875-888.	1.3	11
93	Risk of gastrointestinal bleeding during anticoagulant treatment. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 673-685.	1.0	46
94	Annual Fecal Immunochemical Testing is as Effective as Colonoscopy Every 5 Years for Familial Colorectal Cancer Screening. <i>Gastroenterology</i> , 2017, 152, S542.	0.6	3
95	Non-steroidal anti-inflammatory drug related upper gastrointestinal bleeding: types of drug use and patient profiles in real clinical practice. <i>Current Medical Research and Opinion</i> , 2017, 33, 1815-1820.	0.9	16
96	Correlation between adenoma detection rate in colonoscopy and fecal immunochemical testing based colorectal cancer screening programs. <i>United European Gastroenterology Journal</i> , 2017, 5, 255-260.	1.6	46
97	Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans. <i>Gastroenterology</i> , 2017, 152, 980-982.e3.	0.6	57
98	Inter-Observer Agreement Among Pathologists in the Diagnosis of Sessile Serrated Polyps: A Multi-Center International Study. <i>Gastroenterology</i> , 2017, 152, S538.	0.6	1
99	Familial Colorectal Cancer and Genetic Susceptibility: A Screening of 99 Colorectal Risk Gene Variants in First Degree Relatives of Patients with Colorectal Cancer. <i>Gastroenterology</i> , 2017, 152, S552.	0.6	0
100	Fecal Hemoglobin Concentration, a Good Predictor of Risk of Advanced Colorectal Neoplasia in Symptomatic and Asymptomatic Patients. <i>Gastroenterology</i> , 2017, 152, S548.	0.6	0
101	Reply. <i>Gastroenterology</i> , 2017, 153, 612-613.	0.6	1
102	A Few Spanish Pearls for the American Journal of Gastroenterology. <i>American Journal of Gastroenterology</i> , 2017, 112, 1759-1760.	0.2	0
103	Blocking Nupr1 Protein, A Successful Approach for Pancreatic Adenocarcinoma Treatment. <i>Gastroenterology</i> , 2017, 152, S42.	0.6	0
104	CD24 Expression Is Increased in 5-Fluorouracil-Treated Esophageal Adenocarcinoma Cells. <i>Frontiers in Pharmacology</i> , 2017, 8, 321.	1.6	8
105	New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice. <i>BMC Cancer</i> , 2017, 17, 637.	1.1	33
106	Colorectal cancer population screening programs worldwide in 2016: An update. <i>World Journal of Gastroenterology</i> , 2017, 23, 3632.	1.4	394
107	Relevance of DNA repair gene polymorphisms to gastric cancer risk and phenotype. <i>Oncotarget</i> , 2017, 8, 35848-35862.	0.8	14
108	Protons pump inhibitor treatment and lower gastrointestinal bleeding: Balancing risks and benefits. <i>World Journal of Gastroenterology</i> , 2016, 22, 10477.	1.4	36

#	ARTICLE	IF	CITATIONS
109	Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLoS ONE, 2016, 11, e0160046.	1.1	137
110	Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study. PLoS Medicine, 2016, 13, e1002008.	3.9	20
111	Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells. Frontiers in Pharmacology, 2016, 7, 452.	1.6	20
112	Appropriate prescription, adherence and safety of non-steroidal anti-inflammatory drugs. Medicina Clínica (English Edition), 2016, 146, 267-272.	0.1	3
113	IV Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología Y Hepatología (English Edition), 2016, 39, 697-721.	0.0	27
114	Avances en hemorragia gastrointestinal. Gastroenterología Y Hepatología, 2016, 39, 53-61.	0.2	1
115	Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. Journal of the American College of Cardiology, 2016, 67, 1661-1671.	1.2	69
116	Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial. American Journal of Medicine, 2016, 129, 1002-1005.	0.6	32
117	IV Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterología Y Hepatología, 2016, 39, 697-721.	0.2	97
118	Gastrointestinal Safety of Aspirin for a High-Dose, Multiple-Day Treatment Regimen: A Meta-Analysis of Three Randomized Controlled Trials. Drugs in R and D, 2016, 16, 263-269.	1.1	7
119	Reply. Journal of the American College of Cardiology, 2016, 68, 981-982.	1.2	0
120	Prevention of rebleeding: high-dose PPIs, second-look endoscopy or both?. Endoscopy, 2016, 48, 699-700.	1.0	2
121	We Are Using Too Many PPIs, and We Need to Stop: A European Perspective. American Journal of Gastroenterology, 2016, 111, 1085-1086.	0.2	81
122	Acetylsalicylic Acid Exhibits Antitumor Effects in Esophageal Adenocarcinoma Cells In Vitro and In Vivo. Digestive Diseases and Sciences, 2016, 61, 2896-2907.	1.1	7
123	Long-Term Safety of a Coordinated Delivery Tablet of Enteric-Coated Aspirin 325 mg and Immediate-Release Omeprazole 40 mg for Secondary Cardiovascular Disease Prevention in Patients at High Risk. Cardiovascular Therapeutics, 2016, 34, 59-66.	1.1	6
124	Endoscopist characteristics that influence the quality of colonoscopy. Endoscopy, 2016, 48, 241-247.	1.0	42
125	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease, 2016, 48, 542-551.	0.4	23
126	Systematic Review and Meta-Analysis of Randomised Trials to Ascertain Fatal Gastrointestinal Bleeding Events Attributable to Preventive Low-Dose Aspirin: No Evidence of Increased Risk. PLoS ONE, 2016, 11, e0166166.	1.1	37

#	ARTICLE	IF	CITATIONS
127	Association of <i>PSCA</i> gene variants with poor prognosis and increased susceptibility to gastric cancer and decreased risk of duodenal ulcer disease. <i>International Journal of Cancer</i> , 2015, 137, 1362-1373.	2.3	39
128	Rescuing compound bioactivity in a secondary cell-based screening by using γ -cyclodextrin as a molecular carrier. <i>International Journal of Nanomedicine</i> , 2015, 10, 2249.	3.3	4
129	Editorial (Thematic Issue: Harmful and Beneficial Effect of Aspirin on Gastrointestinal Tract). <i>Current Pharmaceutical Design</i> , 2015, 21, 5047-5048.	0.9	0
130	Aspirin in the 21st century – common mechanisms of disease and their modulation by aspirin: a report from the 2015 scientific conference of the international aspirin foundation, 28 August, London, UK. <i>Ecancelmedscience</i> , 2015, 9, 581.	0.6	4
131	Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 675-681.	0.5	53
132	Deconvolution Analysis for Classifying Gastric Adenocarcinoma Patients Based on Differential Scanning Calorimetry Serum Thermograms. <i>Scientific Reports</i> , 2015, 5, 7988.	1.6	30
133	Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. <i>Endoscopy</i> , 2015, 47, a1-a46.	1.0	603
134	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2024-2025.	2.4	0
135	Risk of Upper and Lower Gastrointestinal Bleeding in Patients Taking Nonsteroidal Anti-inflammatory Drugs, Antiplatelet Agents, or Anticoagulants. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 906-912.e2.	2.4	207
136	Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective. <i>Journal of Gastroenterology</i> , 2015, 50, 626-637.	2.3	24
137	Effect of esomeprazole on gastroduodenal erosions in patients at increased gastrointestinal risk treated with low-dose acetylsalicylic acid: A post-hoc analysis of the OBERON trial. <i>International Journal of Cardiology</i> , 2015, 182, 500-502.	0.8	3
138	NSAIDs and gastrointestinal cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2015, 120, 91-96.	1.0	33
139	Colonic diverticular disease. Treatment and prevention. <i>Gastroenterology & Hepatology</i> , 2015, 38, 590-599.	0.2	15
140	Epidemiology of Low Dose Aspirin Damage in the Lower Gastrointestinal Tract. <i>Current Pharmaceutical Design</i> , 2015, 21, 5094-5100.	0.9	14
141	A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases. <i>Current Pharmaceutical Design</i> , 2015, 21, 5101-5107.	0.9	3
142	Effect of aspirin treatment on the prevention of esophageal adenocarcinoma in a rat experimental model. <i>Oncology Reports</i> , 2014, 31, 2785-2791.	1.2	4
143	Prevention and Treatment of NSAID Gastropathy. <i>Current Treatment Options in Gastroenterology</i> , 2014, 12, 398-413.	0.3	22
144	Liver bioengineering. <i>Organogenesis</i> , 2014, 10, 250-259.	0.4	37

#	ARTICLE	IF	CITATIONS
145	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1708-1716.e4.	2.4	13
146	Safe Prescription Recommendations for Non Steroidal Anti-inflammatory Drugs: Consensus Document Elaborated by Nominated Experts of Three Scientific Associations (SER-SEC-AEG). <i>Reumatolog�a Cl�nica (English Edition)</i> , 2014, 10, 68-84.	0.2	9
147	Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1181-1190.	0.6	10
148	The small bowel, low-dose aspirin and PPIs��should we be concerned?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 458-460.	8.2	7
149	Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. <i>Cancer Causes and Control</i> , 2014, 25, 985-997.	0.8	31
150	Recomendaciones para una prescripci�n segura de antiinflamatorios no esteroideos: documento de consenso elaborado por expertos nominados por 3 sociedades cient�ficas (SER-SEC-AEG). <i>Reumatolog�a Cl�nica</i> , 2014, 10, 68-84.	0.2	21
151	Efficiency of Naproxen/Esomeprazole in Association for Osteoarthritis Treatment in Spain. <i>Reumatolog�a Cl�nica (English Edition)</i> , 2014, 10, 210-217.	0.2	5
152	Genetic susceptibility and gastric cancer risk: The importance of meta-analyses as a statistical tool. <i>Gastroenterolog�a Y Hepatolog�a</i> , 2014, 37, 421-426.	0.2	10
153	Eficiencia de la combinaci�n naproxeno/esomeprazol para el tratamiento de la artrosis en Espa�a. <i>Reumatolog�a Cl�nica</i> , 2014, 10, 210-217.	0.2	14
154	Monitoring Complete Blood Counts and Haemoglobin Levels in Osteoarthritis Patients: Results from a European Survey Investigating Primary Care Physician Behaviours and Understanding. <i>Open Rheumatology Journal</i> , 2014, 8, 110-115.	0.1	2
155	Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights. <i>World Journal of Gastroenterology</i> , 2014, 20, 9439-50.	1.4	37
156	Aspirin, cyclooxygenase inhibition and colorectal cancer. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 40.	0.6	70
157	Gastrointestinal Adverse Effects of Short-Term Aspirin Use: A Meta-Analysis of Published Randomized Controlled Trials. <i>Drugs in R and D</i> , 2013, 13, 9-16.	1.1	28
158	Compliance With Prescriptions of Appropriate Therapy for Nonsteroidal Anti-inflammatory Drug Users: Is the Glass Half Empty or Half Full?. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 505-506.	2.4	0
159	Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. <i>Arthritis Research and Therapy</i> , 2013, 15, S3.	1.6	284
160	Effect of Aspirin and Antiplatelet Drugs on the Outcome of the Fecal Immunochemical Test. <i>Mayo Clinic Proceedings</i> , 2013, 88, 683-689.	1.4	24
161	Much of the Genetic Risk of Colorectal Cancer Is Likely to Be Mediated Through Susceptibility to Adenomas. <i>Gastroenterology</i> , 2013, 144, 53-55.	0.6	41
162	Is NSAID-related gastrointestinal damage preventable?. <i>Journal of Digestive Diseases</i> , 2013, 14, 55-61.	0.7	18

#	ARTICLE	IF	CITATIONS
163	Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. <i>Gastrointestinal Endoscopy</i> , 2013, 77, 381-389.e1.	0.5	125
164	One year intermittent rifaximin plus fibre supplementation vs. fibre supplementation alone to prevent diverticulitis recurrence: A proof-of-concept study. <i>Digestive and Liver Disease</i> , 2013, 45, 104-109.	0.4	67
165	Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. <i>Gastrointestinal Endoscopy</i> , 2013, 78, 333-341.e1.	0.5	62
166	Optimizing the Use of Aspirin for Cardiovascular Prevention. <i>Drugs</i> , 2013, 73, 803-814.	4.9	13
167	Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 285-294.	0.6	6
168	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 482-492.	0.5	102
169	Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies. <i>Journal of the National Cancer Institute</i> , 2013, 105, 878-886.	3.0	25
170	Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation. <i>Thrombosis and Haemostasis</i> , 2013, 110, 1298-1304.	1.8	31
171	Esomeprazole for Prevention and Resolution of Upper Gastrointestinal Symptoms in Patients Treated With Low-dose Acetylsalicylic Acid for Cardiovascular Protection. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 61, 250-257.	0.8	15
172	Importance of adherence to gastroprotection during cyclooxygenase 2 inhibitor treatment. <i>Annals of Gastroenterology</i> , 2013, 26, 270-271.	0.4	0
173	Lower GI bleeding is more common than upper among patients on dual antiplatelet therapy: long-term follow-up of a cohort of patients commonly using PPI co-therapy. <i>Heart</i> , 2012, 98, 718-723.	1.2	65
174	Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. <i>New England Journal of Medicine</i> , 2012, 366, 697-706.	13.9	763
175	Prescription of and Adherence to Non-Steroidal Anti-Inflammatory Drugs and Gastroprotective Agents in At-Risk Gastrointestinal Patients. <i>American Journal of Gastroenterology</i> , 2012, 107, 707-714.	0.2	36
176	Factors associated with gastrointestinal perforation in a cohort of patients with rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1819-1828.	1.5	59
177	Low-dose Aspirin and Cancer Mortality: A Meta-analysis of Randomized Trials. <i>American Journal of Medicine</i> , 2012, 125, 560-567.	0.6	58
178	Aspirin: The balance between benefits and harms. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2012, 26, 97-99.	1.0	0
179	Gastroprotection in NSAID and low-dose aspirin users: A cross-sectional study in primary care. <i>Gastroenterology and Hepatology</i> , 2012, 35, 1-7.	0.2	9
180	Variability in the Management of Nonvariceal Upper Gastrointestinal Bleeding in Europe: An Observational Study. <i>Advances in Therapy</i> , 2012, 29, 1026-1036.	1.3	17

#	ARTICLE	IF	CITATIONS
181	Relevance of GSTM1, GSTT1, and GSTP1 gene polymorphisms to gastric cancer susceptibility and phenotype. <i>Mutagenesis</i> , 2012, 27, 771-777.	1.0	53
182	The APC and PreSAP Trials: A Post Hoc Noninferiority Analysis Using a Comprehensive New Measure for Gastrointestinal Tract Injury in 2 Randomized, Double-Blind Studies Comparing Celecoxib and Placebo. <i>Clinical Therapeutics</i> , 2012, 34, 569-579.	1.1	5
183	Cardiac function and aminoterminal pro- α -brain natriuretic peptide levels in liver-transplanted cirrhotic patients. <i>Clinical Transplantation</i> , 2012, 26, 111-116.	0.8	10
184	Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. <i>World Journal of Gastroenterology</i> , 2012, 18, 4866.	1.4	8
185	Role of gastrin-peptides in Barrett's and colorectal carcinogenesis. <i>World Journal of Gastroenterology</i> , 2012, 18, 6560.	1.4	28
186	Prevention of peptic ulcers with esomeprazole in patients at risk of ulcer development treated with low-dose acetylsalicylic acid: a randomised, controlled trial (OBERON). <i>Heart</i> , 2011, 97, 797-802.	1.2	114
187	Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 762-768.e6.	2.4	136
188	Gastrointestinal effects of aspirin. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2011, 8, 385-394.	8.2	107
189	Should Prophylactic Low-dose Aspirin Therapy be Continued in Peptic Ulcer Bleeding?. <i>Drugs</i> , 2011, 71, 1-10.	4.9	17
190	Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds - Gastrointestinal Adverse Effects. <i>Drugs in R and D</i> , 2011, 11, 277-288.	1.1	38
191	Epidemiology and Demographics of Upper Gastrointestinal Bleeding: Prevalence, Incidence, and Mortality. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2011, 21, 567-581.	0.6	53
192	Barrett's esophagus: natural history. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 292-308.	1.8	11
193	Managing the adverse effects of nonsteroidal anti-inflammatory drugs. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 605-621.	1.3	82
194	Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2011, 4, 365-374.	1.4	18
195	Gastrointestinal bleeding associated with low-dose aspirin use: relevance and management in clinical practice. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 45-54.	1.0	28
196	The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 818-822.	0.5	72
197	Adverse effects of non-steroidal anti-inflammatory drugs (NSAIDs, aspirin and coxibs) on upper gastrointestinal tract. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 121-132.	1.0	505
198	Cost-Effectiveness of Colorectal Cancer Screening in High-Risk Spanish Patients: Use of a Validated Model to Inform Public Policy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2765-2776.	1.1	21

#	ARTICLE	IF	CITATIONS
199	A Novel Composite Endpoint to Evaluate the Gastrointestinal (GI) Effects of Nonsteroidal Antiinflammatory Drugs Through the Entire GI Tract. <i>Journal of Rheumatology</i> , 2010, 37, 167-174.	1.0	72
200	<i>MLH1</i> Founder Mutations with Moderate Penetrance in Spanish Lynch Syndrome Families. <i>Cancer Research</i> , 2010, 70, 7379-7391.	0.4	29
201	Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1453-1458.	0.5	86
202	Clopidogrel with or without Omeprazole in Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2010, 363, 1909-1917.	13.9	1,019
203	A review of the gastrointestinal safety data—a gastroenterologist's perspective. <i>Rheumatology</i> , 2010, 49, ii3-ii10.	0.9	70
204	Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. <i>Lancet</i> , The, 2010, 376, 173-179.	6.3	307
205	Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. <i>Drug, Healthcare and Patient Safety</i> , 2009, 1, 47.	1.0	54
206	Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. <i>Ecological Management and Restoration</i> , 2009, 22, 239-248.	0.2	47
207	Drug-related damage of the ageing gastrointestinal tract. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2009, 23, 849-860.	1.0	17
208	Discovery of Specific Flavodoxin Inhibitors as Potential Therapeutic Agents against <i>Helicobacter pylori</i> Infection. <i>ACS Chemical Biology</i> , 2009, 4, 928-938.	1.6	48
209	Relevance of IL-1 and TNF gene polymorphisms on interleukin-1 β and tumor necrosis factor- α gastric mucosal production. <i>Human Immunology</i> , 2009, 70, 935-945.	1.2	24
210	Myths and facts in the use of anti-inflammatory drugs. <i>Annals of Medicine</i> , 2009, 41, 423-437.	1.5	46
211	Adenoma Recurrence Rates in First-Degree Relatives of Patients with Colorectal Cancer. Do These Patients Need More Intensive Surveillance?. <i>Gastrointestinal Endoscopy</i> , 2009, 69, AB285.	0.5	0
212	Efficacy and safety of piroxicam revisited. A global meta-analysis of randomised clinical trials. <i>Pharmacological Research</i> , 2009, 60, 254-263.	3.1	19
213	Time Trends and Impact of Upper and Lower Gastrointestinal Bleeding and Perforation in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2009, 104, 1633-1641.	0.2	502
214	Nonsteroidal Anti-Inflammatory Drugs and Lower Gastrointestinal Complications. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 333-352.	1.0	147
215	Evidence for Endoscopic Ulcers as Meaningful Surrogate Endpoint for Clinically Significant Upper Gastrointestinal Harm. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1156-1163.	2.4	36
216	Low-Dose Aspirin Affects the Small Bowel Mucosa: Results of a Pilot Study With a Multidimensional Assessment. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 524-529.	2.4	101

#	ARTICLE	IF	CITATIONS
217	NSAIDs and the colon. <i>Current Opinion in Gastroenterology</i> , 2009, 25, 44-49.	1.0	24
218	Nonsteroidal Antiinflammatory Drugs and Cyclooxygenase Inhibition in the Gastrointestinal Tract: A Trip From Peptic Ulcer to Colon Cancer. <i>American Journal of the Medical Sciences</i> , 2009, 338, 96-106.	0.4	84
219	Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications. <i>World Journal of Gastroenterology</i> , 2009, 15, 5953.	1.4	15
220	Noninvasive diagnostic modalities for early detection of colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2008, 4, 24-33.	1.0	1
221	Role of nitric oxide in the gastrointestinal tract. <i>Arthritis Research and Therapy</i> , 2008, 10, S4.	1.6	151
222	A case-control study of the association between polymorphisms of the endothelial nitric oxide synthase and glycoprotein IIIa genes and upper gastrointestinal bleeding in users of low-dose aspirin. <i>Clinical Therapeutics</i> , 2008, 30, 121-130.	1.1	19
223	Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial. <i>Lancet</i> , The, 2008, 372, 1756-1764.	6.3	201
224	Efficacy of Esomeprazole (20 mg Once Daily) for Reducing the Risk of Gastroduodenal Ulcers Associated With Continuous Use of Low-Dose Aspirin. <i>American Journal of Gastroenterology</i> , 2008, 103, 2465-2473.	0.2	193
225	Are COX-2 selective inhibitors safer than NSAIDs for patients with osteoarthritis and rheumatoid arthritis?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, 648-649.	1.7	1
226	Editorial [Hot Topic: COX-2 Inhibition in Gastroenterology and Rheumatology: Current Challenges and Perspectives for the Future (Executive Editor: Angel Lanas)]. <i>Current Pharmaceutical Design</i> , 2007, 13, 2214-2214.	0.9	0
227	Inappropriate Prevention of NSAID-Induced Gastrointestinal Events Among Long-Term Users in the Elderly. <i>Drugs and Aging</i> , 2007, 24, 121-131.	1.3	63
228	Effect of Antisecretory Drugs and Nitrates on the Risk of Ulcer Bleeding Associated With Nonsteroidal Anti-Inflammatory Drugs, Antiplatelet Agents, and Anticoagulants. <i>American Journal of Gastroenterology</i> , 2007, 102, 507-515.	0.2	264
229	Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. <i>Current Medical Research and Opinion</i> , 2007, 23, 163-173.	0.9	151
230	NSAID-induced gastrointestinal damage: Current clinical management and recommendations for prevention. <i>Chinese Journal of Digestive Diseases</i> , 2006, 7, 127-133.	1.1	29
231	Prevention and treatment of NSAID-induced gastroduodenal injury. <i>Current Treatment Options in Gastroenterology</i> , 2006, 9, 147-156.	0.3	17
232	The role of COX-2 in chemoprevention of colorectal cancer: A friend or an enemy?. <i>Current Colorectal Cancer Reports</i> , 2006, 2, 5-12.	1.0	1
233	Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus. <i>Prostaglandins and Other Lipid Mediators</i> , 2006, 81, 150-161.	1.0	26
234	Microbial Flora in NSAID-Induced Intestinal Damage: A Role for Antibiotics?. <i>Digestion</i> , 2006, 73, 136-150.	1.2	79

#	ARTICLE	IF	CITATIONS
235	Prevention of anti-inflammatory drug-induced gastrointestinal damage: Benefits and risks of therapeutic strategies. <i>Annals of Medicine</i> , 2006, 38, 415-428.	1.5	99
236	Gastrointestinal injury from NSAID therapy. <i>Postgraduate Medicine</i> , 2005, 117, 23-31.	0.9	16
237	Association of Helicobacter pylori-related Distal Gastric Cancer with the HLA Class II Gene DQB1*0602 and cagA+ Strains in a Southern European Population. <i>Helicobacter</i> , 2005, 10, 12-21.	1.6	28
238	Editorial [Hot Topic: Benefits, Problems and Alternatives to COX-2 Inhibition (Guest Editor: Angel Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.0	0
239	Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. <i>New England Journal of Medicine</i> , 2005, 352, 1092-1102.	13.9	2,378
240	Genomic rearrangements in and are rare mutational events in Spanish patients with hereditary nonpolyposis colorectal cancer. <i>Cancer Letters</i> , 2005, 225, 93-98.	3.2	17
241	Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus. <i>World Journal of Gastroenterology</i> , 2005, 11, 7436.	1.4	31
242	Free radicals and antioxidant systems in reflux esophagitis and Barrett's esophagus. <i>World Journal of Gastroenterology</i> , 2005, 11, 2697.	1.4	11
243	The Prevalence of Peptic Ulcer not Related to Helicobacter pylori or Non-Steroidal Anti-Inflammatory Drug Use is Negligible in Southern Europe. <i>Helicobacter</i> , 2004, 9, 249-254.	1.6	78
244	Selective COX-2 inhibition is associated with decreased mucosal damage induced by acid and pepsin in rabbit esophagitis. <i>Inflammation</i> , 2003, 27, 21-29.	1.7	13
245	Clinical Implications of COX-1 and / or COX-2 Inhibition for the Distal Gastrointestinal Tract. <i>Current Pharmaceutical Design</i> , 2003, 9, 2253-2266.	0.9	60
246	Risk of upper gastrointestinal bleeding associated with non-aspirin cardiovascular drugs, analgesics and nonsteroidal anti-inflammatory drugs. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 173-178.	0.8	65
247	Atypical and Aggressive Upper Gastrointestinal Ulceration Associated With Aspirin Abuse. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 523-528.	1.1	25
248	Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. <i>Expert Opinion on Drug Safety</i> , 2002, 1, 245-252.	1.0	19
249	Bleeding duodenal ulcer and association with polymorphism of endothelial constitutive nitric oxide synthase gene. <i>Digestive Diseases and Sciences</i> , 2002, 47, 996-1000.	1.1	4
250	Diaphragm Disease of the Small Bowel. <i>Journal of Clinical Gastroenterology</i> , 2001, 32, 344-346.	1.1	37
251	Superoxide anion and nitric oxide in high-grade esophagitis induced by acid and pepsin in rabbits. <i>Digestive Diseases and Sciences</i> , 2001, 46, 2733-2743.	1.1	25
252	Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the risk of complications. <i>European Journal of Gastroenterology and Hepatology</i> , 2001, 13, 623-626.	0.8	7

#	ARTICLE	IF	CITATIONS
253	Prevention and healing of experimental indomethacin-induced gastric lesions. <i>European Journal of Gastroenterology and Hepatology</i> , 2000, 12, 313-318.	0.8	7
254	Nitric oxide and superoxide anion in low-grade esophagitis induced by acid and pepsin in rabbits. <i>Digestive Diseases and Sciences</i> , 2000, 45, 1802-1809.	1.1	19
255	Study of Outcome After Targeted Intervention for Peptic Ulcer Resistant To Acid Suppression Therapy. <i>American Journal of Gastroenterology</i> , 2000, 95, 513-519.	0.2	20
256	Nitrovasodilators, Low-Dose Aspirin, Other Nonsteroidal Antiinflammatory Drugs, and the Risk of Upper Gastrointestinal Bleeding. <i>New England Journal of Medicine</i> , 2000, 343, 834-839.	13.9	374
257	Toxicity of NSAIDs in the stomach and duodenum. <i>European Journal of Gastroenterology and Hepatology</i> , 1999, 11, 375-382.	0.8	37
258	Effect of growth factors and prostaglandin E2 on restitution and proliferation of rabbit esophageal epithelial cells. <i>Digestive Diseases and Sciences</i> , 1998, 43, 2309-2316.	1.1	26
259	Esophageal Motility and Intraesophageal pH Patterns in Patients with Esophagitis and Chronic Nonsteroidal Anti-Inflammatory Drug Use. <i>Journal of Clinical Gastroenterology</i> , 1998, 27, 316-320.	1.1	6
260	Prostaglandin E2 is the major arachidonic acid metabolite secreted by esophageal mucosal cells in rabbits. <i>Inflammation</i> , 1997, 21, 419-429.	1.7	6
261	Reversible Prolonged Skin Bleeding Time in Acute Gastrointestinal Bleeding Presumed Due to NSAIDs. <i>Journal of Clinical Gastroenterology</i> , 1996, 22, 96-103.	1.1	16
262	Effect of Parenteral Omeprazole and Ranitidine on Gastric pH and the Outcome of Bleeding Peptic Ulcer. <i>Journal of Clinical Gastroenterology</i> , 1995, 21, 103-106.	1.1	99
263	Significant Role of Aspirin Use in Patients With Esophagitis. <i>Journal of Clinical Gastroenterology</i> , 1991, 13, 622-627.	1.1	62
264	Safe hospital discharge based on lower GI bleeding scores: a long way to go. <i>AME Medical Journal</i> , 0, 2, 147-147.	0.4	3
265	Analysis and Curation of the Database of a Colo-Rectal Cancer Screening Program. , 0, , .		1